BioCentury
ARTICLE | Clinical News

InflammaGen Shok-Pak: Phase II start

November 7, 2011 8:00 AM UTC

By year end, Leading BioSciences' InflammaGen Therapeutics Inc. company will begin a placebo-controlled Phase II trial to evaluate InflammaGen Shok-Pak in about 200 patients. ...